<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9808008</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20962</journal-id>
<journal-id journal-id-type="nlm-ta">J Hum Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Hum. Genet.</journal-id>
<journal-title-group>
<journal-title>Journal of human genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1434-5161</issn>
<issn pub-type="epub">1435-232X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28228639</article-id>
<article-id pub-id-type="pmc">5637523</article-id>
<article-id pub-id-type="doi">10.1038/jhg.2017.19</article-id>
<article-id pub-id-type="manuscript">NIHMS909911</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>GRIN1</italic> mutation associated with intellectual disability alters NMDA receptor trafficking and function</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Wenjuan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shieh</surname>
<given-names>Christine</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN2">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Swanger</surname>
<given-names>Sharon A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tankovic</surname>
<given-names>Anel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Au</surname>
<given-names>Margaret</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McGuire</surname>
<given-names>Marianne</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tagliati</surname>
<given-names>Michele</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graham</surname>
<given-names>John M</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Madan-Khetarpal</surname>
<given-names>Suneeta</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Traynelis</surname>
<given-names>Stephen F</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Hongjie</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pierson</surname>
<given-names>Tyler Mark</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA</aff>
<aff id="A2">
<label>2</label>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China</aff>
<aff id="A3">
<label>3</label>David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA</aff>
<aff id="A4">
<label>4</label>Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA</aff>
<aff id="A5">
<label>5</label>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA</aff>
<aff id="A6">
<label>6</label>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA</aff>
<aff id="A7">
<label>7</label>Department of Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA</aff>
<aff id="A8">
<label>8</label>Center for Functional Evaluation of Rare Variants, Emory University School of Medicine, Atlanta, GA, USA</aff>
<aff id="A9">
<label>9</label>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence: Dr TM Pierson, Departments of Pediatrics and Neurology, and the Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., ASHP 8401, Los Angeles, CA 90048, USA. <email>tyler.pierson@cshs.org</email></corresp>
<fn id="FN2">
<label>10</label>
<p>These authors are Co-first authors.</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>CONFLICT OF INTEREST</bold>
</p>
<p>SFT is a consultant for Janssen Pharmaceuticals, NeurOp, Inc., and Pfizer Inc, and co-founder of NeurOp Inc. The remaining authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>3</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>12</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>62</volume>
<issue>6</issue>
<fpage>589</fpage>
<lpage>597</lpage>
<!--elocation-id from pubmed: 10.1038/jhg.2017.19-->
<abstract>
<p id="P1">N-methyl-D-aspartate receptors (NMDARs) play important roles in brain development and neurological disease. We report two individuals with similar dominant <italic>de novo GRIN1</italic> mutations (c.1858 G&gt;A and c.1858 G&gt;C; both p.G620R). Both individuals presented at birth with developmental delay and hypotonia associated with behavioral abnormalities and stereotypical movements. Recombinant NMDARs containing the mutant GluN1-G620R together with either GluN2A or GluN2B were evaluated for changes in their trafficking to the plasma membrane and their electrophysiological properties. GluN1-G620R/GluN2A complexes showed a mild reduction in trafficking, a ~ 2-fold decrease in glutamate and glycine potency, a strong decrease in sensitivity to Mg<sup>2+</sup> block, and a significant reduction of current responses to a maximal effective concentration of agonists. GluN1-G620R/GluN2B complexes showed significantly reduced delivery of protein to the cell surface associated with similarly altered electrophysiology. These results indicate these individuals may have suffered neurodevelopmental deficits as a result of the decreased presence of GluN1-G620R/GluN2B complexes on the neuronal surface during embryonic brain development and reduced current responses of GluN1-G620R-containing NMDARs after birth. These cases emphasize the importance of comprehensive functional characterization of <italic>de novo</italic> mutations and illustrates how a combination of several distinct features of NMDAR expression, trafficking and function can be present and influence phenotype.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>